REHOVOT, Israel--(BUSINESS WIRE)--Dec. 22, 2005-- The Companies Are Negotiating the Full Development of the Manufacturing of the Congenital Emphysema Drug with the Italian Company’s Raw Materials. Kamada (TASE:KMDA), a developer, manufacturer and marketer of bio-pharmaceutical prescription drugs, has recently completed the proof of feasibility phase for an Italian company, towards the development of its API prescription drug manufactured with the Italian company’s raw materials. Kamada is already engaged in a more advanced development stage with a French company towards the conjoint production of the company’s flagship drug, API.
